Staphylococcus Research Today is a free monthly online journal that collates and summarizes the latest research about Staphylococcus, including details on mrsa, hospitals, infection, antibiotic resistance, superbugs.

In vitro antistaphylococcal activity of dalbavancin, a novel glycopeptide.

Lopez S, Hackbarth C, Romanò G, Trias J, Jabes D, Goldstein BP

Vicuron Pharmaceuticals, Fremont, CA, USA.

OBJECTIVES: Dalbavancin is a novel, semi-synthetic glycopeptide antibiotic. The aim of this study was to further explore its activity against staphylococci. METHODS: The bactericidal activity of dalbavancin was studied using MBC and time-kill methods. The potential for resistance to dalbavancin was examined using single-step and serial-passage experiments. RESULTS: Dalbavancin was bactericidal against methicillin-susceptible and -resistant Staphylococcus aureus, in both the presence and absence of human serum. No resistance was seen with any isolate tested. After serial passage, bacterial populations were more homogeneous in their susceptibility to dalbavancin than to vancomycin or teicoplanin. CONCLUSION: Dalbavancin is bactericidal for staphylococci. Resistance to this semi-synthetic glycopeptide is not readily developed in vitro.

Published 7 March 2005 in J Antimicrob Chemother, 55: ii21-4.
Full-text of this article is available online (may require subscription).

© 2004-2008 Staphylococcus Research Today. All Rights Reserved.